OCS — Oculis Holding AG stock price, charts and financials

QT23Oculis Holding AG

Oculis Holding AG (NASDAQ: OCS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.77
+0.09+0.73%
OverviewShort InterestFilings
OCSQT23Oculis Holding AG·NASDAQ
12.77+0.73%
News
Up 0.7% — Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand57.17MPerf Week12.11%
Market Cap725.23MForward P/E-EPS next Y-2.18Insider Trans-Shs Float37.03MPerf Month-7.45%
Enterprise Value648.30MPEG-EPS next Q-Inst Own35.94%Short Float4.06%Perf Quarter-59.22%
Income-114.22MP/S-EPS this Y-Inst Trans-Short Ratio2.07Perf Half Y-53.87%
Sales624.12KP/B3.08EPS next Y-1.14%ROA-39.08%Short Interest1.51MPerf YTD-36.50%
Book/sh-P/C-EPS next 5Y-ROE-57.09%52W High34.74 -63.23%Perf Year-30.33%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-42.07%52W Low10.60 20.53%Perf 3Y1.52%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-2889.37%Volatility5.11% 5.21%Perf 5Y31.33%
Dividend TTM-EV/Sales-EPS Y/Y TTM11.61%Oper. Margin-16740.95%ATR (14)0.74Perf 10Y-
Dividend Ex-Date-Quick Ratio5.18Sales Y/Y TTM-Profit Margin-18861.29%RSI (14)52.04Recom2.00
Dividend Gr. 3/5Y-Current Ratio5.18EPS Q/Q18.18%SMA206.49%Beta0.24Target Price38.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-0.24%Rel Volume0.54Prev Close12.68
Employees60LT Debt/Eq0.01EarningsNov 05SMA200-41.77%Avg Volume687.17KPrice12.77
IPO DateMay 18, 2021Option/ShortYes / YesEPS/Sales Surpr.-23.13% -2.48%Net Debt/EBITDA0.66Volume370,877Change0.73%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26ReiteratedRobert W. Baird$49 → $38
Jun-01-26ReiteratedNeedhamBuy$38
Jun-01-26ReiteratedGuggenheimBuy$45
Jun-01-26ReiteratedHC Wainwright & Co.Buy$47 → $26
May-20-26InitiatedGuggenheimBuy
May-12-26ReiteratedHC Wainwright & Co.Buy$36 → $47
Mar-04-26ReiteratedStifel Nicolaus$40 → $50
Dec-19-25ReiteratedStifel Nicolaus$40
Oct-08-25ReiteratedChardan CapitalBuy
Oct-07-25ReiteratedHC Wainwright & Co.Buy$33 → $36
Latest News
Today
Today03:01AM
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Companyglobenewswire.com
Aug-06-26
Aug-06-2611:36PM
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimateszacks.com
04:05PM
Oculis Reports Q2 2026 Financial Results and Provides Company Updateglobenewswire.com
Aug-03-26
Aug-03-2604:01AM
Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis DataBenzinga
04:00AM
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapsesglobenewswire.com
Jul-21-26
Jul-21-2602:20AM
OCS Group to buy Mitie for $4.17 billionreuters.com
Jul-17-26
Jul-17-2608:02AM
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga
Jul-08-26
Jul-08-2604:05PM
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilitiesglobenewswire.com
Jul-02-26
Jul-02-2604:00AM
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conferenceglobenewswire.com
Company

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Ownership
Total institutional ownership35.94%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue010———
Cost of Goods Sold Incl. D&A0590———
Gross Profit0-580———
Selling, General and Administrative Excl. Other302516———
Research and Development665933———
Other Operating Expense-1-5941———
Operating Income-95-83-90———
Interest Expense112———
Unusual Expense
——————
Non-Operating Income (Expense)-18-14-7———
Net Income Before Taxes-114-98-99———
Income Taxes
000———
Consolidated Net Income-114-98-99———
Net Income From Continuing Operations-114-98-99———
Net Income-114-98-99———
EPS (Recurring)-2.18-2.41-3.31———
EPS (Basic, Before Extraordinaries)-2.18-2.41-3.31———
EPS (Diluted)-2.18-2.41-3.31———
EBITDA-112-97-97———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio—680.00————
Gross Margin—-5,800.00————
Operating Margin—-8,300.00————
Net Margin—-9,800.00————
Shares Outstanding524030———
Market Capitalization1,038680337———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.